Omega-3 Dosage in Cardiovascular Trials

The dose ladder, in one place

Cochrane's 2018 review is the widest view available. It took in 79 randomized trials with 112,059 participants and accepted anything from 0.5 g a day to more than 5 g, with 16 trials giving at least 3 g. All-cause mortality came in at a risk ratio of 0.98 (0.90 to 1.03). Cardiovascular events came in at 0.99 (0.94 to 1.04) and cardiovascular death at 0.95 (0.87 to 1.03). Coronary heart disease events looked better at 0.93 (0.88 to 0.97), but that didn't survive sensitivity analysis.

A meta-regression found no dose gradient for death or events.

That's the awkward part.

What 1 g a day did

VITAL randomized 25,871 US adults to 1 g of marine omega-3 daily, supplying 460 mg of EPA and 380 mg of DHA, or placebo. Over a median 5.3 years the primary composite of major cardiovascular events came in at a hazard ratio of 0.92, with a 95% confidence interval of 0.80 to 1.06. Total myocardial infarction, a secondary endpoint, was lower at 0.72 (0.59 to 0.90). Stroke and cardiovascular death didn't move. ASCEND randomized 15,480 adults with diabetes to 1 g a day or olive oil for a mean of 7.4 years, and serious vascular events occurred in 8.9% against 9.2%, a rate ratio of 0.97 (0.87 to 1.08).

Two large trials, one gram, no signal.

GISSI-Prevenzione is the older exception. It randomized 11,324 people within three months of a myocardial infarction to 1 g a day of a mixture supplying 850 mg of EPA and 882 mg of DHA, and reported a relative risk of 0.90 (0.82 to 0.99) for death, nonfatal heart attack, or stroke over 3.5 years. Only about 5% of those patients were on a statin at baseline. Modern statin use is why it doesn't transfer.

The 1.8 g EPA trial that worked

JELIS randomized 18,645 Japanese adults with high cholesterol to a statin alone or a statin plus 1.8 g a day of purified EPA, given as 600 mg three times daily. Over a mean of 4.6 years, major coronary events occurred in 2.8% against 3.5%, a hazard ratio of 0.81 (0.69 to 0.95). The design was open label with blinded endpoint review, and the statin dose was low by current standards.

OMEMI tested a similar gram range in 1,027 older adults after a heart attack, using 1.8 g a day of an EPA plus DHA mixture for 2 years. It came out at a hazard ratio of 1.08 (0.82 to 1.41). Same milligrams, different molecule, different answer.

The 4 g split

REDUCE-IT randomized 8,179 statin-treated adults with triglycerides between 135 and 499 mg/dL and either established cardiovascular disease or diabetes plus one more risk factor. They received 2 g of icosapent ethyl twice daily with food, which is 4 g a day of a purified EPA ethyl ester with no DHA in it. The primary composite occurred in 17.2% against 22.0% over a median 4.9 years, a hazard ratio of 0.75 (0.68 to 0.83). Amarin Pharma, which sells the product, funded the trial.

STRENGTH randomized 13,078 similar patients to 4 g a day of an omega-3 carboxylic acid formulation carrying about 2.2 g of EPA and 0.8 g of DHA, or corn oil. The primary endpoint came in at 12.0% against 12.2%, hazard ratio 0.99 (0.90 to 1.09), and the trial stopped for futility.

Same dose. Opposite answer.

Three explanations have published support. DHA may blunt some of EPA's effect, though no outcome trial has tested that head on. REDUCE-IT reached higher blood EPA, roughly a 394% rise against about 269% in STRENGTH. And the mineral oil placebo in REDUCE-IT appears to have pushed LDL cholesterol up in the control arm, which would inflate the apparent benefit.

Prescription grams and capsule grams

A standard fish oil softgel says 1,000 mg on the front. The Supplement Facts panel behind it usually lists 180 mg of EPA plus 120 mg of DHA, which is 300 mg of the fatty acids the trials measured. So 4 g of combined EPA and DHA takes about 13 capsules. REDUCE-IT's 4 g of EPA alone, with the DHA stripped out, would take about 22 capsules of that same product, and you still couldn't get there, because every capsule brings DHA along.

Nobody assembles a prescription course out of a retail bottle.

The FDA has concluded that supplements providing up to 5 g a day of combined EPA and DHA are safe when used as directed, and notes that 2 to 15 g a day of EPA or DHA may lengthen bleeding time. That's a safety limit, not a target.

Safety at the top of the range

Atrial fibrillation is the signal that held up. REDUCE-IT hospitalized 3.1% of treated patients for atrial fibrillation or flutter against 2.1% on placebo. STRENGTH reported a hazard ratio of 1.69 (1.29 to 2.21). The effect appeared whether or not the cardiovascular benefit is real. Serious bleeding was 2.7% against 2.1%, short of significance, while STRENGTH recorded gastrointestinal adverse events in 24.7% of the treated group against 14.7% on corn oil.

One shared safety signal.

What a dose comparison can't settle

Pooling by milligram assumes the molecule doesn't matter. The REDUCE-IT and STRENGTH pair is the cleanest evidence that something beyond the gram count does.

It also assumes the patients are interchangeable. VITAL enrolled generally healthy adults, while REDUCE-IT enrolled people with residual risk on a statin and elevated triglycerides. A null result in the first group says nothing about the second.

Frequently asked questions

Is 1 g of fish oil a day enough?

For cardiovascular prevention, the trials that tested about 1 g a day didn't reduce events. VITAL and ASCEND were both large and both null on their primary endpoints.

How much EPA and DHA is in a standard capsule?

A 1,000 mg softgel typically carries 180 mg of EPA and 120 mg of DHA. Read the panel, not the front.

Why did REDUCE-IT succeed where STRENGTH failed?

Three candidates have published support: the absence of DHA, the higher blood EPA level reached, and the mineral oil placebo. No trial has been built to separate them.

Can I take 4 g a day from supplements?

The FDA's guidance tops out at 5 g a day of combined EPA and DHA, and higher intakes can lengthen bleeding time. That's a ceiling, not a target.

---

This article is for general information only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Talk with your health care provider before using omega-3 supplements, especially if you take prescription medication.

Sources

• Abdelhamid AS et al., Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease, Cochrane Database Syst Rev 2018
• Bhatt DL et al., Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia, NEJM 2019
• Nicholls SJ et al., Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events, JAMA 2020
• Manson JE et al., Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer, NEJM 2019
• ASCEND Study Collaborative Group, Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus, NEJM 2018
• Yokoyama M et al., Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS), Lancet 2007